Stock listing
NASDAQ:IXHL Incannex Healthcare Inc. Stock
Home listing (NASDAQ) of Incannex Healthcare Inc.
Follow Incannex Healthcare Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:IXHL
$1.86 USD +0.11 (+6.3%)
Close on Nov 20, 2026
- Day range
- $1.69 – $1.99 USDNov 20, 2026
- Volume
- 219,817 sharesNov 20, 2026
- Market cap
- $23.33M USDAt the close on Nov 20, 2026 · price × 12.54M shares outstanding
- 52-week range
- $1.61 – $14.91 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $258,425 USDMedian day 68,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:IXHL · Home | $1.86 USD | +0.11 (+6.3%) | 219,817 | $1.75 | $1.99 | $1.69 | $1.75 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IXHL · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.86 | +0.11 | +6.3% | $1.75 | $1.99 | $1.69 | 219,817 | |
| $1.75 | +0.01 | +0.6% | $1.71 | $1.987 | $1.61 | 233,831 | |
| $1.74 | -0.19 | -9.8% | $1.90 | $1.906 | $1.72 | 158,657 | |
| $1.93 | -0.04 | -2.0% | $1.90 | $2.01 | $1.90 | 111,040 | |
| $1.97 | -0.05 | -2.5% | $1.984 | $2.07 | $1.91 | 100,222 | |
| $2.02 | +0.045 | +2.3% | $1.99 | $2.06 | $1.955 | 103,637 | |
| $1.975 | -0.035 | -1.7% | $2.06 | $2.10 | $1.96 | 65,176 | |
| $2.01 | -0.18 | -8.2% | $2.21 | $2.21 | $1.96 | 184,705 | |
| $2.19 | -0.05 | -2.2% | $2.28 | $2.28 | $2.16 | 88,914 | |
| $2.24 | -0.03 | -1.3% | $2.32 | $2.32 | $2.16 | 106,215 | |
| $2.27 | -0.22 | -8.8% | $2.48 | $2.64 | $2.24 | 119,537 | |
| $2.49 | -0.015 | -0.6% | $2.55 | $2.661 | $2.49 | 36,452 | |
| $2.505 | +0.125 | +5.3% | $2.40 | $2.55 | $2.40 | 65,963 | |
| $2.38 | -0.14 | -5.6% | $2.55 | $2.633 | $2.17 | 148,804 | |
| $2.52 | -0.06 | -2.3% | $2.58 | $2.617 | $2.50 | 102,450 | |
| $2.58 | -0.13 | -4.8% | $2.685 | $2.737 | $2.58 | 53,307 | |
| $2.71 | +0.09 | +3.4% | $2.65 | $2.79 | $2.62 | 47,726 | |
| $2.62 | +0.01 | +0.4% | $2.56 | $2.69 | $2.56 | 64,568 | |
| $2.61 | -0.03 | -1.1% | $2.64 | $2.67 | $2.588 | 56,595 | |
| $2.64 | +0.04 | +1.5% | $2.58 | $2.69 | $2.57 | 38,536 | |
| $2.60 | -0.16 | -5.8% | $2.73 | $2.75 | $2.55 | 138,400 | |
| $2.76 | +0.015 | +0.5% | $2.78 | $2.81 | $2.75 | 30,700 | |
| $2.745 | -0.015 | -0.5% | $2.74 | $2.86 | $2.735 | 51,200 | |
| $2.76 | -0.06 | -2.1% | $2.80 | $2.85 | $2.75 | 68,300 | |
| $2.82 | -0.06 | -2.1% | $2.88 | $2.939 | $2.815 | 28,800 | |
| $2.88 | +0.02 | +0.7% | $2.84 | $2.90 | $2.75 | 86,700 | |
| $2.86 | -0.05 | -1.7% | $2.91 | $2.93 | $2.84 | 79,500 | |
| $2.91 | +0.01 | +0.3% | $2.95 | $2.991 | $2.88 | 57,300 | |
| $2.90 | -0.20 | -6.5% | $3.04 | $3.10 | $2.85 | 148,600 | |
| $3.10 | -0.10 | -3.1% | $3.17 | $3.243 | $3.088 | 43,400 | |
| $3.20 | +0.02 | +0.6% | $3.17 | $3.25 | $3.13 | 47,600 | |
| $3.18 | +0.01 | +0.3% | $3.134 | $3.20 | $3.13 | 26,400 | |
| $3.17 | -0.04 | -1.2% | $3.20 | $3.30 | $3.13 | 62,200 | |
| $3.21 | 0.00 | 0.0% | $3.18 | $3.23 | $3.15 | 27,900 | |
| $3.21 | -0.04 | -1.2% | $3.32 | $3.332 | $3.20 | 52,100 | |
| $3.25 | +0.01 | +0.3% | $3.23 | $3.33 | $3.20 | 41,000 | |
| $3.24 | -0.07 | -2.1% | $3.35 | $3.35 | $3.20 | 35,900 | |
| $3.31 | +0.16 | +5.1% | $3.18 | $3.35 | $3.157 | 43,700 | |
| $3.15 | -0.17 | -5.1% | $3.26 | $3.27 | $3.13 | 130,200 | |
| $3.32 | -0.08 | -2.4% | $3.38 | $3.38 | $3.26 | 145,200 | |
| $3.40 | -0.045 | -1.3% | $3.47 | $3.47 | $3.365 | 60,000 | |
| $3.445 | +0.05 | +1.5% | $3.38 | $3.54 | $3.37 | 73,600 | |
| $3.395 | -0.095 | -2.7% | $3.48 | $3.60 | $3.38 | 63,000 | |
| $3.49 | -0.15 | -4.1% | $3.64 | $3.72 | $3.48 | 90,100 | |
| $3.64 | +0.05 | +1.4% | $3.58 | $3.72 | $3.42 | 92,200 | |
| $3.59 | -0.21 | -5.5% | $3.79 | $3.79 | $3.421 | 184,800 | |
| $3.80 | +0.35 | +10.1% | $3.45 | $3.84 | $3.45 | 382,100 | |
| $3.45 | +0.16 | +4.9% | $3.29 | $3.52 | $3.29 | 128,300 | |
| $3.29 | +0.03 | +0.9% | $3.29 | $3.40 | $3.25 | 84,200 | |
| $3.26 | +0.01 | +0.3% | $3.25 | $3.32 | $3.20 | 58,200 | |
| $3.25 | +0.02 | +0.6% | $3.23 | $3.345 | $3.17 | 50,800 | |
| $3.23 | -0.14 | -4.2% | $3.33 | $3.398 | $3.22 | 36,800 | |
| $3.37 | +0.125 | +3.9% | $3.30 | $3.443 | $3.26 | 49,500 | |
| $3.245 | -0.005 | -0.2% | $3.22 | $3.31 | $3.22 | 45,800 | |
| $3.25 | -0.02 | -0.6% | $3.27 | $3.294 | $3.13 | 77,200 | |
| $3.27 | +0.09 | +2.8% | $3.20 | $3.33 | $3.191 | 34,200 | |
| $3.18 | -0.17 | -5.1% | $3.35 | $3.40 | $3.17 | 157,200 | |
| $3.35 | -0.29 | -8.0% | $3.58 | $3.615 | $3.35 | 80,000 | |
| $3.64 | -0.05 | -1.4% | $3.70 | $3.785 | $3.58 | 42,700 | |
| $3.69 | -0.01 | -0.3% | $3.71 | $3.76 | $3.65 | 60,600 | |
| $3.70 | -0.05 | -1.3% | $3.71 | $3.85 | $3.69 | 87,800 | |
| $3.75 | +0.13 | +3.6% | $3.61 | $3.94 | $3.61 | 201,200 | |
| $3.62 | +0.05 | +1.4% | $3.51 | $3.66 | $3.41 | 60,800 | |
| $3.57 | -0.05 | -1.4% | $3.62 | $3.65 | $3.514 | 70,200 | |
| $3.62 | +0.18 | +5.2% | $3.38 | $3.62 | $3.35 | 76,900 |
Splits
1 split · NASDAQ:IXHL · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-30 | Consolidation |
- Ticker
- NASDAQ:IXHL
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 1, 2026
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26
Latest deck · Mar 12, 2026
Investor Presentation (March 2026)
Investor deck · 36 slides
Latest news
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26
Oct 1, 2026
Closed $3.25 (+0.3%) on Oct 1, 2026
Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position
Sep 9, 2026
Closed $3.23 (-4.2%) on Sep 9, 2026
Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X
Aug 25, 2026
Closed $3.75 (+3.6%) on Aug 25, 2026
Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea
Jul 23, 2026
Closed $3.16 (+1.3%) on Jul 23, 2026
Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea
Jun 25, 2026
Closed $3.20 (-1.5%) on Jun 25, 2026
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility
Jun 10, 2026
Closed $3.91 (+6.5%) on Jun 10, 2026
Incannex Announces Initiation of Research Coverage by Alliance Global Partners
Jun 9, 2026
Closed $3.67 (+7.9%) on Jun 9, 2026
Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea
May 14, 2026
Closed $3.88 (+0.8%) on May 14, 2026
Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness
Apr 22, 2026
Closed $4.09 (+8.5%) on Apr 22, 2026
Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position
Mar 27, 2026
Closed $3.24 (-5.0%) on Mar 27, 2026
Incannex Healthcare Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 22 in the last 12 months · 120 in all · newest Oct 1, 2026 · oldest 2022
- Decks
- 7 decks · latest Mar 12, 2026
Where Incannex Healthcare Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:IXHL · Home listing · This page | NASDAQ | United States | USD |
| BOATS:IXHL | BOATS | United States | USD |
Valuation
Price/book 0.3× against a median of 1.4×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$44.85M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.98
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Incannex Healthcare Inc. · NASDAQ:IXHL | US$23.33M | −US$44.85M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.98 |
| Original Biomedicals Co Ltd · TPEX:6483 | US$23.81M | US$21.67M | n/a | 1,875× | n/a | 7.1× | n/a | 0.0× | n/a |
| Sernova Biotherapeutics Inc · TSX:SVA | US$23.70M | US$25.46M | n/a | n/a | n/a | n/a | n/a | n/a | 0.40 |
| Scynexis, Inc. · NASDAQ:SCYX | US$23.69M | −US$21.66M | n/a | −1.1× | n/a | 0.4× | −53.5% | 0.0× | 1.76 |
| ImmuPharma plc · LSE:IMM | US$23.68M | US$22.77M | n/a | n/a | n/a | 9.9× | n/a | 0.0× | n/a |
| Organoidsciences Ltd. · KRX:476040 | US$23.46M | US$6.52M | n/a | 3.8× | n/a | 1.1× | −814.8% | 0.4× | n/a |
| Immutep Ltd · ASX:IMM | US$23.41M | −US$24.93M | n/a | −2.6× | n/a | 0.6× | −544.8% | 0.0× | n/a |
| ABVC BioPharma, Inc. · NASDAQ:ABVC | US$23.37M | US$25.81M | n/a | n/a | n/a | 1.8× | n/a | 0.2× | 1.39 |
| Actinogen Medical Limited · ASX:ACW | US$23.08M | US$15.17M | n/a | n/a | n/a | 1.6× | n/a | 0.2× | n/a |
| BioNxt Solutions Inc · CSE:BNXT | US$22.78M | US$22.72M | n/a | n/a | n/a | n/a | n/a | n/a | 0.22 |
| Polyrizon Ltd. · NASDAQ:PLRZ | US$22.61M | US$7.56M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.67 |
| Median of the others | US$23.44M | US$18.42M | 1.4× | 1.4× | −544.8% | 0.0× | 0.67 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 18.17 USD · Analysts' mean
- EPS, year to Jun 2027
- -2.23 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Joel Latham | President and Chief Executive Officer |
| Joseph Swan | Chief Financial Officer |
| Parisa Asvadi | Vice President, Research and Development |
| Lekhram Changoer | Chief Technology Officer |
| Lou Barbato | Chief Medical Officer |
| Mark Bleackley | Chief Scientific Officer |
| Natalie May | Head of Clinical Operations |
Board
| Director | Role |
|---|---|
| Troy Valentine | Board Chair |
| George Anastassov | Board Member |
| Joel Latham | President and Chief Executive Officer |
| Peter Widdows | Board Member |
| Robert Clark | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2027 | Nov 12, 2026 · Before open | +2.3% |
| Q4 2026 | Sep 25, 2026 · Before open | −2.4% |
| Q3 2026 | May 15, 2026 · Before open | +2.1% |
| Q2 2026 | Feb 13, 2026 · Before open | 0.0% |
| Q1 2026 | Nov 14, 2025 · Before open | −1.4% |
| Q4 2025 | Sep 29, 2025 · After close | −10.6% |
| Q3 2025 | May 15, 2025 · Before open | −61.6% |
| Q2 2025 | Feb 14, 2025 · Before open | −0.9% |
| Q1 2025 | Nov 14, 2024 · After close | −14.5% |
| Q2 2024 | Feb 26, 2024 · Before open | +2.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (March 2026) | Investor deck | 36 slides | Mar 12, 2026 |
| Investor Presentation (February 2026) | Investor deck | 27 slides | February 2026 |
| Corporate Update (May 2023) | Corporate update | 32 slides | May 18, 2023 |
| Technical Presentation (May 2023) | Technical | 16 slides | May 3, 2023 |
| Investor Presentation (August 2022) | Investor deck | 36 slides | Aug 9, 2022 |
| Technical Presentation (June 2022) | Technical | 28 slides | Jun 3, 2022 |
| Merger or Acquisition (May 2022) | Merger or acquisition | 27 slides | May 12, 2022 |
Financings
| Raise | Date |
|---|---|
| At-the-market programme of shares of common stock Tranche closed: at-the-market programme | Jul 31, 2025 |
| At-the-market programme of shares sold through At-The-Market (ATM) facility Closed: at-the-market programme Use of proceeds: To fund the cancellation of all remaining Series A Warrants | Jun 12, 2025 |
| At-the-market programme of shares sold through at-the-market (ATM) facility Closed: US$16.7M raised Use of proceeds: $12.5 million to cancel up to 50.4% of the Series A Warrants issued in a prior financing, reducing potential dilution | May 20, 2025 |
| Private placement of common stock (or common stock equivalents) and Series A common stock warrants Announced: about US$12.5M · US$1.08 a share · ½ warrant at US$2.16 for 30 months · R. F. Lafferty & Co., Inc. Dealers: R. F. Lafferty & Co., Inc. (lead) Use of proceeds: Clinical trials incl. IHL-42X U.S. Phase 2 completion and Phase 3 expansion, repaying convertible debentures, working capital and general corporate purposes | Mar 7, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Withdrawn on Jan 21, 2022. Filed with the SEC to go public on Aug 17, 2021.
- ADSs offered
- 2,600,000 American depositary shares
- Underwriters' option
- Up to 390,000 more ADSs
- Listing
- IXHL on the Nasdaq Capital Market · Has applied to list
- Underwriter
- Roth Capital Partners
Steps
| Step | When |
|---|---|
| Filed publicly | Aug 17, 2021 |
| Amended 4 times | Newest Dec 7, 2021 |
| Filing withdrawn | Jan 21, 2022 |
Filings
| Filing | Filed |
|---|---|
| RW · Request to withdraw a registration | Jan 21, 2022 |
| F-1/A · Registration statement, amended | Dec 7, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Nov 30, 2021 |
| F-1/A · Registration statement, amended | Nov 23, 2021 |
| F-1/A · Registration statement, amended | Nov 3, 2021 |
| F-1/A · Registration statement, amended | Sep 28, 2021 |
| F-1 · Registration statement | Aug 17, 2021 |
Open IPO · From the cover of the amended prospectus (F-1/A) filed Dec 7, 2021
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 86.0K | 12.0K | 1.01M | 785.2K | 1.90M | 599.7K | 1.18M | 1.01M | 283.0K |
| Cost of revenue | 240.0K | 246.0K | 103.0K | 88.1K | 6.33K | 912.0K | 446.5K | 583.2K | 522.8K | 518.3K |
| Gross profit | -240.0K | -160.0K | 12.0K | -88.1K | 778.8K | 985.6K | 153.2K | 597.3K | 487.0K | -235.3K |
| Research and development | 5.21M | 10.7M | 12.9M | 6.31M | 5.37M | 4.65M | 1.46M | 516.8K | ||
| Selling, general and administrative | 17.8M | 12.7M | 24.0M | 10.0M | 7.43M | 3.44M | 1.77M | 1.90M | 2.47M | 2.20M |
| Operating income | -23.0M | -23.8M | -30.0M | -49.7M | -11.4M | -8.24M | -4.11M | -2.79M | -3.21M | -21.0M |
| Depreciation and amortization | 240.0K | 246.0K | 103.0K | 88.0K | 11.4M | 10.2M | 34.8K | 42.5K | 55.0K | 32.3K |
| EBITDA | -22.8M | -23.5M | -29.9M | -49.6M | 0 | 1.95M | -4.08M | -2.75M | -3.16M | -21.0M |
| Interest expense | 0 | 303.0K | 3.01K | 218 | 2.68K | 90 | 85.2K | 12.9K | 50.0K | |
| Income before tax | -19.3M | -46.9M | -18.4M | -48.8M | -14.9M | -8.16M | -3.90M | -2.87M | -3.20M | -21.1M |
| Income tax | 0 | 0 | 30.0K | -567.4K | -2.68K | 488.3K | -151.6K | -262.7K | -305.8K | |
| Net income | -19.3M | -46.9M | -18.5M | -48.8M | -14.9M | -8.16M | -4.66M | -2.72M | -2.94M | -20.8M |
| Earnings per share, basic | -1.66 | -40.82 | -1.15 | -3.32 | -1.50 | -0.33 | -0.27 | -0.73 | -1.55 | -19.52 |
| Earnings per share, diluted | -1.66 | -40.82 | -1.15 | -3.32 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 67.7M | 15.0M | 5.86M | 22.1M | 37.5M | 6.85M | 2.48M | 93.7K | 229.6K | 508.7K |
| Short-term investments | 166.6K | |||||||||
| Receivables | 4.63M | 10.0M | 287.5K | 318.8K | 127.0K | 284.0K | 84.3K | 10.5K | 8.12K | |
| Inventory | -10.0M | -416.2K | -337.5K | -178.1K | 125.9K | 153.4K | 223.8K | 227.4K | ||
| Current assets | 72.8M | 20.0M | 16.2M | 23.0M | 38.0M | 7.01M | 2.91M | 384.7K | 541.9K | 842.4K |
| Property, plant and equipment | 4.00K | 227.0K | 472.0K | 294.0K | 85.4K | 97.7K | ||||
| Goodwill | -17.8M | |||||||||
| Total assets | 73.0M | 20.4M | 17.0M | 23.8M | 38.0M | 7.01M | 2.91M | 520.0K | 711.5K | 1.00M |
| Accounts payable | 1.13M | 6.07M | 527.0K | 2.63M | 1.31M | 175.1K | 405.5K | 377.7K | 497.5K | 537.6K |
| Current liabilities | 1.49M | 6.98M | 5.62M | 2.55M | 2.02M | 567.3K | 736.4K | 939.0K | 1.10M | 774.3K |
| Total debt | 96.0K | 258.0K | 373.0K | 784.2K | 65.3K | 201.0K | 398.9K | |||
| Total liabilities | 5.61M | 7.06M | 5.83M | 2.96M | 2.02M | 567.3K | 736.4K | 939.0K | 1.10M | 1.17M |
| Shareholders' equity | 67.4M | 13.4M | 11.2M | 20.8M | 36.0M | 6.44M | 2.17M | -418.9K | -385.3K | -169.5K |
| Shares outstanding | 12.5M | 6.48M | 17.6M | 15.9M | 9.93M | 24.5M | 17.1M | 3.73M | 1.90M | 1.06M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -12.9M | -12.5M | -15.8M | -10.7M | -12.9M | -6.87M | -3.89M | -2.21M | -3.00M | -2.70M |
| Capital spending | -10.0K | -8.00K | -277.0K | -316.0K | -5 | -4 | -476.9K | -24.5K | -50.1K | -50.3K |
| Free cash flow | -12.9M | -12.5M | -16.1M | -11.1M | -12.9M | -6.91M | -3.89M | -2.19M | -3.05M | -2.75M |
| Cash from investing | -94.0K | -8.00K | -277.0K | -316.0K | -476.9K | 29.3K | 12.9K | -24.5K | -50.1K | 3.02M |
| Cash from financing | 65.9M | 21.4M | 0 | 8.18M | 41.2M | 12.3M | 7.37M | 2.10M | 2.76M | 183.2K |
| Dividends paid | 0 | 0 | ||||||||
| Share buybacks | -9.40M | 0 | ||||||||
| Change in cash | 52.9M | 8.88M | -16.1M | -2.89M | 28.4M | 5.80M | 3.49M | -177.5K | -283.4K | 504.3K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Oct 27, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Oct 27, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 27, 2026 | Meeting notice | SEC |
| 10-K · Annual report | Sep 25, 2026 | Annual report | SEC |
| 8-K · Current report | Sep 9, 2026 | Current report | SEC |
| 8-K · Current report | Aug 25, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 11, 2026 | Current report | SEC |
| 8-K · Current report | Jul 23, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Jun 25, 2026 | Current report | SEC |
| 8-K · Current report | Jun 10, 2026 | Current report | SEC |
| 8-K · Current report | Jun 9, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Current report | SEC |
| 8-K · Current report | May 12, 2026 | Current report | SEC |
| 8-K · Current report | Apr 22, 2026 | Current report | SEC |
| 8-K · Current report | Mar 27, 2026 | Current report | SEC |
| 8-K · Current report | Mar 25, 2026 | Current report | SEC |
| 8-K · Current report | Mar 18, 2026 | Current report | SEC |
| 8-K · Current report | Mar 17, 2026 | Current report | SEC |
| 424B5 · Prospectus | Mar 12, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 12, 2026 | Material contract | SEC |
| 8-K · Current report | Mar 12, 2026 | Current report | SEC |
| 8-K · Current report | Feb 25, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Feb 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jan 29, 2026 | Current report | SEC |
| 8-K · Current report | Jan 22, 2026 | Current report | SEC |
| 8-K · Current report | Jan 15, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jan 15, 2026 | Current report | SEC |
| 8-K · Current report | Jan 14, 2026 | Current report | SEC |
| 8-K · Current report | Dec 18, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Dec 18, 2025 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Dec 16, 2025 | Meeting notice | SEC |
| 8-K · Current report | Dec 3, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Nov 14, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 30, 2025 | Current report | SEC |
| ARS · Annual report to shareholders | Oct 27, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Oct 27, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 27, 2025 | Meeting notice | SEC |
| 8-K · Current report | Oct 22, 2025 | Current report | SEC |
| 8-K · Current report | Oct 22, 2025 | Current report | SEC |
| 10-K · Annual report | Sep 29, 2025 | Annual report | SEC |
| 8-K · Current report | Aug 26, 2025 | Current report | SEC |
| 8-K · Current report | Aug 22, 2025 | Current report | SEC |
| 8-K · Current report | Aug 8, 2025 | Current report | SEC |
| 8-K · Current report | Jul 31, 2025 | Current report | SEC |
| 8-K · Current report | Jul 30, 2025 | Current report | SEC |
| 8-K · Current report | Jul 25, 2025 | Current report | SEC |
| 8-K · Current report | Jul 24, 2025 | Current report | SEC |
| 424B5 · Prospectus | Jul 24, 2025 | Offer document | SEC |
| S-3MEF | Jul 24, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 24, 2025 | Current report | SEC |
| 8-K · Current report | Jun 18, 2025 | Current report | SEC |
| 8-K · Current report | Jun 17, 2025 | Current report | SEC |
| 8-K · Current report | Jun 13, 2025 | Current report | SEC |
| 8-K · Current report | Jun 12, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jun 4, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 3, 2025 | Current report | SEC |
| 8-K · Current report | May 29, 2025 | Current report | SEC |
| 8-K · Current report | May 28, 2025 | Current report | SEC |
| 424B5 · Prospectus | May 28, 2025 | Offer document | SEC |
| 8-K · Current report | May 28, 2025 | Material contract | SEC |
| 8-K · Current report | May 20, 2025 | Current report | SEC |
| 8-K · Current report | May 20, 2025 | Current report | SEC |
| 424B5 · Prospectus | May 20, 2025 | Offer document | SEC |
| 8-K · Current report | May 16, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | May 15, 2025 | Meeting notice | SEC |
| 8-K · Current report | May 15, 2025 | Material contract | SEC |
| 8-K · Current report | May 15, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | Apr 29, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 29, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Apr 28, 2025 | Offer document | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 25, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Apr 24, 2025 | Other filings | SEC |
| PRER14A | Apr 17, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Apr 16, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 16, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 7, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Apr 7, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 3, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | Apr 2, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 2, 2025 | Other filings | SEC |
| S-3 · Registration statement | Mar 24, 2025 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Mar 18, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 18, 2025 | Material contract | SEC |
| D | Mar 14, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Mar 10, 2025 | Material contract | SEC |
| 8-K · Current report | Feb 14, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Feb 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Feb 4, 2025 | Current report | SEC |
| 8-K · Current report | Jan 23, 2025 | Current report | SEC |
| 8-K · Current report | Jan 10, 2025 | Current report | SEC |
| 8-K · Current report | Dec 11, 2024 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | Dec 9, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Dec 6, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 4, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Nov 26, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 25, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 20, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 15, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| UPLOAD · Letter from the SEC | Nov 13, 2024 | Other filings | SEC |
| ARS · Annual report to shareholders | Nov 12, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Nov 12, 2024 | Meeting notice | SEC |
| S-3 · Registration statement | Nov 6, 2024 | Offer document | SEC |
| S-3 · Registration statement | Nov 6, 2024 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Oct 31, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Oct 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 24, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 24, 2024 | Current report | SEC |
| 8-K · Current report | Oct 24, 2024 | Management or board change | SEC |
| 8-K · Current report | Oct 21, 2024 | Financing | SEC |
| 8-K · Current report | Oct 15, 2024 | Material contract | SEC |
| 8-K · Current report | Sep 30, 2024 | Current report | SEC |
| 10-K · Annual report | Sep 30, 2024 | Annual report | SEC |
| 8-K · Current report | Sep 10, 2024 | Current report | SEC |
| 8-K · Current report | Sep 10, 2024 | Material contract | SEC |
| RW · Request to withdraw a registration | Sep 10, 2024 | Other filings | SEC |
| 8-K · Current report | Aug 5, 2024 | Current report | SEC |
| 5 · Annual statement of ownership | Aug 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 30, 2024 | Current report | SEC |
| S-1/A · Registration statement, amended | Jul 17, 2024 | Offer document | SEC |
| S-1 · Registration statement | Jul 3, 2024 | Offer document | SEC |
| 8-K · Current report | May 30, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2024 | Current report | SEC |
| 8-K · Current report | Apr 16, 2024 | Current report | SEC |
| 8-K · Current report | Mar 5, 2024 | Management or board change | SEC |
| 8-K · Current report | Feb 28, 2024 | Current report | SEC |
| 8-K · Current report | Feb 16, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Feb 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Feb 1, 2024 | Current report | SEC |
| 8-K · Current report | Jan 24, 2024 | Current report | SEC |
| 8-K · Current report | Jan 18, 2024 | Current report | SEC |
| 8-K · Current report | Jan 17, 2024 | Current report | SEC |
| 8-K · Current report | Dec 22, 2023 | Current report | SEC |
| 4 · Change in ownership | Dec 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 21, 2023 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Dec 20, 2023 | Offer document | SEC |
| 8-K · Current report | Dec 15, 2023 | Current report | SEC |
| 3/A · Initial statement of ownership, amended | Dec 8, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 6, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 6, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 6, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 6, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 6, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 6, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 6, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 6, 2023 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Dec 1, 2023 | Other filings | SEC |
| 8-K · Current report | Nov 29, 2023 | Material contract | SEC |
| POS AM · Amendment to an effective registration | Nov 29, 2023 | Offer document | SEC |
| 15-12G | Nov 29, 2023 | Other filings | SEC |
| 25-NSE/A | Nov 29, 2023 | Other filings | SEC |
| 25-NSE | Nov 28, 2023 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Nov 24, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 20, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 16, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 16, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 16, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 8, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 7, 2023 | Current report | SEC |
| 20-F · Annual report | Oct 31, 2023 | Annual report | SEC |
| 6-K · Report of a foreign issuer | Oct 26, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 18, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 10, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 5, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 8, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 1, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 31, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 23, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 22, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 10, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 8, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 31, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 27, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 25, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 20, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 18, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 13, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 10, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 5, 2023 | Current report | SEC |
This page holds 200 of 267 filings. Open Filings
Cap table
Built by 6ix from Incannex Healthcare Inc.’s releases · as of Sep 24, 2026
- Common shares
- 12,544,627
- Fully diluted
- 12,544,627
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 12,544,627 | Sep 24, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Sep 24, 2026 | 12,544,627 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Lekhram Changoer Other companies: AXIM Biotechnologies, Inc. (Director · Apr 23, 2015 – Dec 31, 2016 · Past) | Chief Technology Officer · Since at least Nov 28, 2023 |
| George Anastassov | Board Member · Since at least Nov 14, 2025 |
| Joel Latham | President and Chief Executive Officer · Since at least Nov 28, 2023 |
| Joseph Swan | Chief Financial Officer · Since at least Nov 28, 2023 |
| Lou Barbato | Chief Medical Officer · Since at least May 14, 2026 |
| Luigi M Barbato | Chief Medical Officer · Oct 21, 2024 – Oct 23, 2024 · Past |
| Madhukar Bhalla | Secretary and CFO · Nov 28, 2023 – Nov 28, 2023 · Past |
| Mark Bleackley | Chief Scientific Officer · Since at least Dec 3, 2025 |
| Natalie May | Head of Clinical Operations · Since at least Nov 5, 2026 |
| Parisa Asvadi | Vice President, Research and Development · Since at least Nov 5, 2026 |
All 13 people
| Person | Seat |
|---|---|
| Peter Widdows | Board Member · Since at least Nov 28, 2023 |
| Robert Clark | Director · Since at least Nov 28, 2023 |
| Troy Valentine | Director · Since at least Nov 14, 2025 |
Log in to ask 6ix AI your own questions about Incannex Healthcare Inc.